Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 19, 2007

Novacea Snags Rights to Oncology Agent from Kudos and BTG

  • Novacea gained access to Kudos Pharmaceuticals’ anticancer agent. AQ4N (banoxantrone) is currently in Phase I evalution in patients with advanced oesophageal cancer.

    "The extensive preclinical and clinical data generated to date gives us confidence in the significant opportunity AQ4N presents as an anticancer agent in multiple tumor types and hematological malignancies," states John P. Walker, chairman and interim CEO of Novacea.

    As part of the agreement, Novacea will acquire an exclusive license and worldwide development and commercialization rights for the candidate. Kudos anticipates it will complete patient recruitment for its ongoing Phase I trials with AQ4N around the middle of 2007.

    Kudos obtained a worldwide license for AQ4N from BTG in March 2002 and subsequently licensed the North American rights to Novacea in December 2003.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »